A novel bispecific antibody targeting CD3 and prolactin receptor (PRLR) against PRLR-expression breast cancer

BACKGROUND: Prolactin receptor (PRLR) is highly expressed in a subset of human breast cancer and prostate cancer, which makes it a potential target for cancer treatment. In clinical trials, the blockade of PRLR was shown to be safe but with poor efficacy. It is therefore urgent to develop new therap...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Exp Clin Cancer Res
Autori principali: Zhou, Yuexian, Zong, Huifang, Han, Lei, Xie, Yueqing, Jiang, Hua, Gilly, John, Zhang, Baohong, Lu, Huili, Chen, Jie, Sun, Rui, Pan, Zhidi, Zhu, Jianwei
Natura: Artigo
Lingua:Inglês
Pubblicazione: BioMed Central 2020
Soggetti:
Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7216678/
https://ncbi.nlm.nih.gov/pubmed/32398042
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-020-01564-4
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi